National Research Corporation's Q4 Results: Revenue and EPS Decline Amid Aggressive Capital Return

National Research Corporation (NRC Health), a leading provider of analytics and insights for healthcare organizations, recently announced its fourth quarter 2024 financial results, revealing a decline in revenue and earnings per share (EPS) amid an aggressive capital return strategy. The company reported revenue of approximately $36.9 million, down from $38.0 million in the same quarter of 2023, and EPS of $0.28, compared to $0.36 in the previous year.

During the quarter, NRC Health returned approximately $10.1 million to stockholders through dividends and stock repurchases. The company repurchased approximately 393,000 shares for approximately $7.3 million and paid a regular quarterly dividend of $0.12 per share, totaling about $2.8 million. However, the company's net indebtedness increased to approximately $58.5 million, which could limit financial flexibility for potential growth investments or market downturns.